Lumos Pharma, Inc.

Good morning, and welcome to Lumos Pharma's Topline Results conference call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded. I will now turn the call over to Lisa Miller, Senior Director of Investor Relations.

Thank you, Operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward looking statements under US federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release we issued yesterday and in our Form 8-K, which may be accessed from the Investors page of the company's website. Speaking on today's call will be Rick Hawkins, CEO and Chairman, John McHugh, our President and Chief Scientific Officer, Dr. Duke Patuk Chuanant, Senior Vice President of Global Clinical and Medical Affairs, and Lori Lawley, Chief Financial Officer. I will now turn the call over to Rick.

Thank you, Lisa, and good morning, everyone. After the market closed yesterday, we issued a press release announcing top-line results from our Phase II Oral Growth 210 and Oral Growth 212 trials of Oral Loom 201 and Pediatric Growth Hormone Deficiency, or PGHV. I'm pleased to report that all primary and secondary endpoints were met in both trials, and data from these trials provide supportive evidence to... Ladies and gentlemen, please stand by.